Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
Sage Rejects Biogen Bid, Launches Review of Alternatives
Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...
Nature6y
Milestones in multiple sclerosis: Biogen’s commitment to advancing the field
As an independent biotechnology company, Biogen (Cambridge, MA) has led innovation in treatment and outcomes assessment in MS for >25 years and continues to have an enduring commitment to elevate ...
Hosted on MSN1mon
Biogen Stock: Is BIIB Underperforming the Healthcare Sector?
Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology company specializing in developing and delivering innovative therapies.